The current status of tardive dyskinesia

Australian and New Zealand Journal of Psychiatry

Volumn 34, Issue 3, 2000, Pages 355-369

  Sachdev, Perminder S ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Antipsychotic drugs; Free radical mechanisms; Pathophysiology; Schizophrenia; Tardive dyskinesia

Indexed keywords

4 AMINOBUTYRIC ACID; AMPHETAMINE; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOPAMINE RECEPTOR; FREE RADICAL; HALOPERIDOL; LEVODOPA; METOCLOPRAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PROCHLORPERAZINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

AGE; HUMAN; NEUROTOXICITY; PATHOPHYSIOLOGY; RECEPTOR SENSITIVITY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA; THEORY;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; CHOLINERGIC ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; FREE RADICALS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, DOPAMINE; RISK FACTORS; SCHIZOPHRENIA;

EID: 0034087775     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2000.00737.x     Document Type: Review

References (96)

1. Schonecker M. Ein eigentuemliches Syndrom im oralen Bereich hei Megaphenapplikation. Nervenarzt 1957; 28:35-36.
2. Faurbye A, Rasch PJ, Bender Peterson P, Brandenborg G, Pakkengerg H. Neurological symptoms in the pharmacotherapy of psychoses. Acta Psychiatrica Scandinavica 1964; 40:10-26.
3. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guilford Press, 1982.
4. Kruk J, Sachdev P, Singh S. Respiratory dyskinesia: a review and five new cases. Journal of Neuropsychiatry and Clinical Neurosciences 1995; 7:223-229.
5. Kane JM, Jeste DV, Barnes TRE et al. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington: American Psychiatric Press, 1992.
6. Burke RE, Farm S, Jankovic J et al. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32:1335-1346.
7. Sachdev PS. Risk factors for tardive dystonia: a case control comparison with tardive dyskinesia. Acta Psychiatrica Scandinavica 1993; 88:98-103.
8. Adityanjee MD, Aderibige YA, Jampula VC, Mathews T. The current status of tardive dystonia. Biological Psychiatry 1999; 45:715-730.
9. Sachdev P. Akathisia and restless legs. New York: Cambridge University Press, 1995.
10. Thaker GK, Nguyen JA, Tamminga CA. Increased saccadic distractability in tardive dyskinesia: functional evidence for subcortical GABA dysfunction. Biological Psychiatry 1988; 1:49-59.
11. Waddington JL, Youssef HA, Dolphin C, Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Archives of General Psychiatry 1987; 44:907-912.
12. Chouinard G, Jones B, Annable L. Neuroleptic-induced supersensitivity psychoses. American Journal of Psychiatry 1978; 135:1409-1410.
13. Wilson I, Garbutt J, Lanier C, Moylan J, Nelson W, Prange AJ Jr. Is there a tardive dysmentia? Shizophrenia Bulletin 1983; 9:187-192.
14. Gualtieri C, Quade D, Hicks R, Mayo JP, Shroeder SR Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. American Journal of Psychiatry 1984; 141:20-23.
15. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia [letter]. Archives of General Psychiatry 1982; 39:486-487.
16. Guy W. Abnormal Involuntary Movements Scale (AIMS). ECDEU Assessment manual for psychopharmacology. Washington: United States Government Printing Office, 1976: 534-537.
17. Ayd FJ. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association 1961; 175:154-1060.
18. Villeneuve A. The rabbit syndrome: a peculiar extrapyramidal reaction. Canadian Psychiatric Association Journal 1972; 17 (Suppl. 2):SS69-SS72.
19. Clayton AH. Antidepressant-induced tardive dyskinesia: review and case report. Psychopharmacological Bulletin 1995; 31:259-264.
20. Leo RJ. Movement disorders associated with serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 1996; 57:449-454.
21. Klawans HL, Barr A. Prevalence of spontaneous lingual-facial-buccal dyskinesias in the elderly. Neurology 1982; 32:558-559.
22. Kane JM, Weinhold P, Kinon B, Wegher J, Leader M. Prevalence of abnormal involuntary movements ('spontaneous dyskinesias') in the normal elderly. Psychopharmacology 1982; 77:105-108.
23. Waddington JL, Crow TJ. Abnormal involuntary movements and psychosis in the preneuroleptic era and in unmedicated patients: implications for the concept of tardive dyskinesia. In: Wolf ME, Mosnaim AD, eds. Tardive dyskinesia: biological mechanisms and clinical aspects. Washington: American Psychiatric Press, 1988:49-66.
24. Kraepelin EP. Dementia praecox and paraphrenia. Barclay RM, trans. Robertson GM, ed. Edinburgh: E and S Livingstone, 1919.
25. Chorfi M, Moussaoui D. Les schizophrenes jamais traites n'ont pas de movements anormaux type dyskinesie tardive. Encephale 1985; 11:263-265.
26. Owens DGC, Johnstone EC, Frith CD. Spontaneous disorders of voluntary movement. Archives of General Psychiatry 1982; 39:643-650.
27. Chatterjee A, Chakos M, Koreen A et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-treated schizophrenic patients. American Journal of Psychiatry 1995; 152:1724-1729.
28. Gervin M, Browne S, Lane A et al. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. American Journal of Psychiatry 1998; 155:1202-1206.
29. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bulletin 1992; 18:701-715.
30. Woerner M, Kane JM, Lieberman J et al. The prevalence of tardive dyskinesia. Journal of Clinical Psychopharmacology 1991; 11:34-42.
31. McDermid SA, Hood J, Bockus S, Dalessandro E. Adolescents on neuroleptic medication - is this population at risk for tardive dyskinesia? Canadian Journal of Psychiatry 1998; 43:629-631.
32. McAndrew JB, Case Q, Treffert DA. Effects of prolonged phenothiazine intake on psychotic and other hospitalized children. Journal of Autism and Childhood Schizophrenia 1972; 2:75-91.
33. Polizos P, Engelhardt D. Dyskinetic phenomena in children treated with psychotropic medications. Psychopharmacological Bulletin 1978; 14:65-68.
34. Paulsen JS, Caligiuri MP, Palmer B, McAdams LA, Jeste DV. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study. Psychopharmacology 1996; 123:307-314.
35. Byne W, White L, Parella M, Adams R, Harvey PD, Davis KL. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. International Journal of Geriatric Psychiatry 1998; 13:473-479.
36. Gualtieri CT, Schroeder SR, Hicks RE, Quade D. Tardive dyskinesia in young mentally retarded individuals. Archives of General Psychiatry 1986; 43:335-340.
37. Sachdev PS. Drug-induced movement disorders in institutionalized adults with mental retardation: clinical characteristics and risk factors. Australian and New Zealand Journal of Psychiatry 1992; 26:242-248.
38. Jeste DV, Caliguiri MP, Paulsen JS et al. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Archives of General Psychiatry 1995; 52:756-765.
39. Chouinard G, Annable L, Mercier P, Ross-Chouinard A. Moore P. A five-year follow-up study of tardive dyskinesia. Psychopharmacological Bulletin 1986; 22:259-263.
40. Gardos G, Cole JO, Haskell D, Marby D, Paine SS. The natural history of tardive dyskinesia. Journal of Clinical Psychopharmacology 1988; 8:31-33.
41. Bergen JA, Eyland EA, Campbell JA et al. The course of tardive dyskinesia in patients on long-term neuroleptics. British Journal of Psychiatry 1989; 154:523-528.
42. Casey DE, Gardos G. Tardive dyskinesia: outcome at 10 years [abstract]. Schizophrenia Research 1990; 3:11.
43. Vagi G, Takamuja M, Kauba S, Kanijima K. Mortality rates of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study. Keio Journal of Medicine (Tokyo) 989; 38:70-72.
44. Smith JM, Baldessarini RJ. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry 1980; 37:1368-1373.
45. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry 1993; 50:723-733.
46. Smith JM, Oswald WT, Kucharski LT, Waterman LJ. Tardive dyskinesia: age and sex differences in hospitalized schizophrenics. Psychopharmacology 1978; 58:207-211.
47. Pandurangi AK, Aderibigbe YA. Tardive dyskinesia in non-western countries - a review. European Archives of Psychiatry and Clinical Neuroscience 1995; 246:47-52.
48. Sachdev PS. Blinking-blepharospasm after chronic neuroleptic treatment. Medical Journal of Australia 1989; 150:341-343.
49. Davis K, Berger P, Hollister L. Tardive dyskinesia and depressive illness. Psychopharmacologlcal Communications 1976; 2:125-130.
50. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. In, Casey DE. Chase TN, Christensen AV et al. Dyskinesia - research and treatment Berlin: Springer-Verlag, 1985:72-78.
51. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacological Bulletin 1984; 20:39-40.
52. Sachdev PS. Depression-dependent exacerbation of tardive dyskinesia. British Journal of Psychiatry 1989; 155:253-255.
53. Trelles L, Trelles JO, Castaneda C, Castro C. Disappearance of tardive dyskinesia in a manic attack. (French) Revue Neurologique 1985; 5:415-416.
54. Casey DE, Keepers GA. Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. In: Casey DE. Christensen AV, eds. Psychopharmacology: current trends Berlin: Springer-Verlag, 1988:74-93.
55. Glazer VM. Clinical outcomes of pharmacotherapy for schizophrenia and implications for health economics. Journal of Clinical Psychiatry Monographs 1997; 15:22-23.
56. van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk? Acta Psychiatrica Scandinavica 1997; 6:206-216.
57. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic treated diabetics. Archives of General Psychiatry 1991; 48:259-263.
58. Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ. Diabetes and development of tardive dyskinesia. American Journal of Psychiatry 1993; 150:966-968.
59. Nilsson A, Waller L, Rosengren A, Adlerherth A, Wilhelmsen L. Cigarette smoking is associated with abnormal involuntary movements in the general male population - a study of men born in 1933. Biological Psychiatry 1997; 41:717-723.
60. Kane J, Woerner M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacological Bulletin 1986; 22:254-258.
61. Andreassen OA, MacEwen T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology 1997; 131:174-179.
62. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schziphrenia. Molecular Psychiatry 1997; 2:139-145.
63. Caliguiri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV. Incidence and risk factors for severe tardive dyskinesia in older patients. British Journal of Psychiatry 1997; 171:148-158.
64. Baldessarini RJ, Cohen BM, Teicher MM. Significance of neuroleptic doses and plasma levels in the pharmacological treatment of psychosis. Archives of General Psychiatry 1988; 45:79-91.
65. Woerner M, Kane JM, Lieberman J et al. The prevalence of tardive dyskinesia. Journal of Clinical Psychoparmacology 1991; 11;34-42.
66. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia - observations from human and animal model studies. Journal of Clinical Psychiatry 1994; 55:102-106.
67. Nair CJ, Abraham G, Stanilla JK et al. Therapeutic effects of clozapine on tardive dyskinesia. Cognitive and Behavioural Practice 1998; 5:123-131.
68. Gutierrez-Esteinou R, Grebb JA. Risperidone: an analysis of the first three years in general use. International Clinical Psychopharmacology 1997; 12 (Suppl. 4):S3-S10.
69. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 1997; 154:1248-1254.
70. Goldman MB, Luchins DJ. Intermittent neuroleptic therapy and tardive dyskinesia: a literature review. Hospital and Community Psychiatry 1984; 35:1215-1219.
71. Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year follow-up. British Medical Journal 1989; 298:985-990.
72. Pert A, Rosenblatt JE, Sivit C, Pert CB, Bunney WE Jr. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 1979; 135:509-514.
73. Klawans HL, Goetz CG, Perlik S. Tardive dyskinesia: review and update. American Journal of Psychiatry 1980; 137:900-908.
74. Butt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196:326-328.
75. Scatton B. Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration. European Journal of Pharmacology 1977; 46:363-369.
76. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatrica Scandnavica 1988; 77:369-378.
77. Gunne LM, Haggstrom JE, Sjokvist B. Association with persistent neuroleptic-induced dyskinesia of regional changes in the brain GABA synthesis. Nature 1984; 309:347-349.
78. Andersson U, Haggstrom JE, Levi ED, Bondessan U, Valverius M, Gunne LM. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Movement Disorders 1989; 4:37-46.
79. Thaker GK, Tamminga CA, Alphs LA, Lafferman J, Ferraro TN, Hare TA. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Archives of General Psychiatry 1987; 44:522-529.
80. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Annals of the New York Academy Sciences 1989; 570:178-185.
81. Gunne LM, Andren PE. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clinical Neuropharmacology 1993; 16:90-95.
82. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biological Psychiatry 1990; 28:535-539.
83. Egan ME, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophrenia Bulletin 1997; 23:583-609.
84. Lohr JB, Lavori P. Whither vitamin E and tardive dyskinesia? Biological Psychiatry 1998; 43:861-862.
85. Adler LA, Edson R, Lavori P et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biological Psychiatry 1998; 43:868-872.
86. Carlsson M, Carlsson A. Interaction between glutamatergic and monoaminergic systems within the basal ganglia -implications for schizophrenia and Parkinson's disease. Trends in Neurosciences 1990; 13:272-276.
87. Tsai G, Goff DC, Chang RW, Flood J, Bear L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. American Journal of Psychiatry 1998; 155:1207-1213.
88. Gardos G, Cole JO. The treatment of tardive dyskinesias. In: Bloom FE. Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress New York: Raven Press. 1995; 1503-1511.
89. Soni SD, Freeman HL, Bamrah JS, Sampath G. Oxypertine in tardive dyskinesia: a long-term controlled study. Acta Psychiatrica Scandinavica 1986; 74:446-450.
90. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48:358-362.
91. Weetman J, Anderson IM, Gregory RP, Gill SS. Bilateral posteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonea. Journal of Neurology, Neurosurgery and Psychiatry 1997; 63:554-556.
92. Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. Pallidotomy for tardive dyskinesia. Lancet 1997; 349:777-778.
93. Gibson AC. Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection. Acta Psychiatrica Scandinavica 1981; 297:111-116.
94. Yassa R, Nair V, Schwartz G. Tardive dyskinesia; a two-year follow up study. Psychosomatics 1984; 25:852-855.
95. Chakos MH, Alvir JMJ, Woerner MG et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry 1996; 53:313-319.
96. Woerner MG, Ma J, Alvir J. Saltz BL, Lieberman JA, Kane JM, Prospective study of tardive dyskinesia in the elderly. Rates and Risk Factors. American Journal of Psychiatry 1998; 155:1521-1528.